Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell

Bon, Serge-Daniel Le; Konopnicki, Déborah; Pisarski, Nathalie; Prunier, Léa; Lechien, Jérôme R.; Horoi, Mihaéla

doi:10.1007/s00405-020-06520-8

Cited by 80 publications

(99 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, it is essential to identify specific therapies that can prevent the chronicity of chemosensitive disorders in Covid-19 patients. 22,23…”

Section: Discussionmentioning

confidence: 99%

“…On the basis of the present study, it is possible to state that the spontaneous recovery margins of a chemosensitive disorder, especially if severe, after two months from clinical onset are very poor. For this reason, we do not consider that there are any reasons to further delay any specific treatment 22,23,27 beyond this time limit.…”

Section: Discussionmentioning

confidence: 99%

“…Some authors reported that systemic steroids and steroid rinses may be effective in the management of Covid-19 related olfactory dysfunctions. 22,23,27,28 Furthermore, olfactory training is recommended to Covid-19 patients with loss of smell for more than two weeks. 28 The efficacy of alpha-lipoic acid, omega-3 supplements and retinoic acid derivatives has not yet found unequivocal indications that recommend their use in patients with Covid-19 related olfactory dysfunctions.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study

et al. 2021

View full text Add to dashboard Cite

Background The long-term recovery rate for coronavirus disease 2019 related chemosensory disturbances has not yet been clarified. Methods Olfactory and gustatory functions were assessed with psychophysical tests in patients in the first seven days from coronavirus disease 2019 onset and one, two, three and six months after the first evaluation. Results A total of 300 patients completed the study. The improvement in olfactory function was significant at the two-month follow up. At the end of the observation period, 27 per cent of the patients still experienced a persistent olfactory disturbance, including anosmia in 5 per cent of cases. As for taste, the improvement in the psychophysical scores was significant only between the baseline and the 30-day control. At the 6-month evaluation, 10 per cent of the patients presented with a persistent gustatory disturbance with an incidence of complete ageusia of 1 per cent. Conclusion Six months after the onset of coronavirus disease 2019, about 6 per cent of patients still had a severe persistent olfactory or gustatory disturbance.

show abstract

“…For this reason, it is essential to identify specific therapies that can prevent the chronicity of chemosensitive disorders in Covid-19 patients. 22,23…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This is a kit containing 24 different types of odors in eight categories. The test result is reported as a number from 0 to 24, which determines the function of the sense of smell in the range of anosmia (0-9), severe microsmia [10] , [11] , [12] , [13] , mild microsmia [14] , [15] , [16] , [17] , [18] , and normosmia [19] , [20] , [21] , [14] . This measure was administered at baseline and the fourth week of the study.…”

Section: Methodsmentioning

confidence: 99%

Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial

Kasiri

Rouhani

Salehifar

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

The aim of this study was to evaluate the usage of mometasone furoate nasal spray in the recovery of patients with severe microsmia or anosmia induced by COVID-19. This was a prospective clinical trial on non-hospitalized adult patients with COVID-19 (> 18 years) who had severe microsmia or anosmia within two weeks. The subjects were randomly assigned to the mometasone furoate group (100 mcg twice daily) or sodium chloride group (0.9%); both groups also received olfactory training for 4 weeks. The primary outcome was the improvement of the olfactory score at the end of the study. Visual analog scale (VAS) and the University of Pennsylvania Smell Identification Test (UPSIT) were used to assess primary outcome. A total of 80 patients were recruited, 77 of them completed the study and were analyzed. There was no statistically significant difference in terms of demographics and baseline clinical characteristics. The olfactory scores (based on VAS) at weekly intervals showed a significant difference between the two groups (P:0.318, <0.001, <0.001, <0.001, respectively). The analyses also showed significant within-group differences from baseline. Nevertheless, the changes were not significant between the two groups (P: 0.444, 0.402, 0.267, 0.329). There was no significant difference between the two groups in terms of the UPSIT results (p> 0.239). However, a significant between-group difference was noted in the severity of loss of smell (P <0.001). Compared to olfactory training, mometasone furoate nasal spray combination with olfactory training showed a higher improvement in severe chronic anosmia by COVID-19.

show abstract

“…Some guidance regarding the treatment of PVOD due to SARS-CoV-2 has already appeared. A small prospective study demonstrated benefit from a short course of oral corticosteroids in addition to olfactory training, but not from olfactory training alone [18]. The British Rhinological Society expert panel has published consensus guidelines on the management of new onset loss of smell with COVID-19 [19].…”

mentioning

confidence: 99%

Post-viral Anosmia (Loss of Sensation of Smell) Did Not Begin with COVID-19!

Dicpinigaitis

2021

Lung

View full text Add to dashboard Cite

Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell

Cited by 80 publications

References 22 publications

Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study

Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study

Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial

Post-viral Anosmia (Loss of Sensation of Smell) Did Not Begin with COVID-19!

Contact Info

Product

Resources

About